{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:16:30Z","timestamp":1787584590700,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["BJ-2021-230"],"award-info":[{"award-number":["BJ-2021-230"]}]},{"name":"Beijing Natural Science Foundation","award":["L242150"],"award-info":[{"award-number":["L242150"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-025-00557-y","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:49:24Z","timestamp":1741967364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of different dosages of rituximab for myasthenia gravis: a single-arm meta-analysis"],"prefix":"10.1007","volume":"33","author":[{"given":"Jianchun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9461-0453","authenticated-orcid":false,"given":"Pengfei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"557_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019. https:\/\/doi.org\/10.1038\/s41572-019-0079-y.","journal-title":"Nat Rev Dis Primers"},{"key":"557_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3.","journal-title":"Lancet Neurol"},{"key":"557_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102712","author":"AM Lascano","year":"2021","unstructured":"Lascano AM, Lalive PH. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev. 2021. https:\/\/doi.org\/10.1016\/j.autrev.2020.102712.","journal-title":"Autoimmun Rev"},{"key":"557_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016. https:\/\/doi.org\/10.1056\/NEJMra1602678.","journal-title":"N Engl J Med"},{"key":"557_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016. https:\/\/doi.org\/10.1212\/WNL.0000000000002790.","journal-title":"Neurology"},{"key":"557_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve. 2017. https:\/\/doi.org\/10.1002\/mus.25597.","journal-title":"Muscle Nerve"},{"key":"557_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.314","author":"D Anderson","year":"2016","unstructured":"Anderson D, Phan C, Johnston WS, Siddiqi ZA. Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up. Ann Clin Transl Neurol. 2016. https:\/\/doi.org\/10.1002\/acn3.314.","journal-title":"Ann Clin Transl Neurol"},{"key":"557_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4190","author":"KR Robeson","year":"2017","unstructured":"Robeson KR, Kumar A, Keung B, et al. Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis. JAMA Neurol. 2017. https:\/\/doi.org\/10.1001\/jamaneurol.2016.4190.","journal-title":"JAMA Neurol"},{"key":"557_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2020.11.043","author":"T Li","year":"2021","unstructured":"Li T, Zhang G, Li Y, et al. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis. J Clin Neurosci. 2021. https:\/\/doi.org\/10.1016\/j.jocn.2020.11.043.","journal-title":"J Clin Neurosci"},{"key":"557_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.725700","author":"X Feng","year":"2021","unstructured":"Feng X, Song Z, Wu M, et al. Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis. Front Neurol. 2021. https:\/\/doi.org\/10.3389\/fneur.2021.725700.","journal-title":"Front Neurol"},{"key":"557_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.736190","author":"C Zhao","year":"2021","unstructured":"Zhao C, Pu M, Chen D, et al. Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis. Front Neurol. 2021. https:\/\/doi.org\/10.3389\/fneur.2021.736190.","journal-title":"Front Neurol"},{"key":"557_CR12","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021.\u00a0https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"557_CR13","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1009-881X.2020.02.012","author":"F Fei","year":"2020","unstructured":"Fei F. Clinical observation of rituximab combined with bromopyrimethamine in the treatment of myasthenia gravis. Chin J Hemorheol. 2020. https:\/\/doi.org\/10.3969\/j.issn.1009-881X.2020.02.012.","journal-title":"Chin J Hemorheol"},{"key":"557_CR14","unstructured":"Anning L. Effects of rituximab on drug-resistant myasthenia gravis. Health Lit. 2022;67\u20139."},{"issue":"1","key":"557_CR15","first-page":"5","volume":"27","author":"W Jiexi","year":"2020","unstructured":"Jiexi W. Analysis of the clinical efficacy of rituximab in myasthenia gravis treatment. Chin J Neuroimmunol Neurol. 2020;27(1):5.","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"557_CR16","unstructured":"Sijia Z. The Clinical Observation of RTX Treating Myasthenia Gravis. Air Force Medical University. 2018."},{"key":"557_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0851","author":"S Brauner","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA, et al. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol. 2020. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0851.","journal-title":"JAMA Neurol"},{"key":"557_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.12.004","author":"V Afanasiev","year":"2017","unstructured":"Afanasiev V, Demeret S, Bolgert F, et al. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients. Neuromuscul Disord. 2017. https:\/\/doi.org\/10.1016\/j.nmd.2016.12.004.","journal-title":"Neuromuscul Disord"},{"key":"557_CR19","doi-asserted-by":"publisher","unstructured":"Piehl F,\u00a0Eriksson-Dufva A, Budzianowska A, et al.\u00a0Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial.\u00a0JAMA Neurol.\u00a02022.\u00a0https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","DOI":"10.1001\/jamaneurol.2022.2887"},{"key":"557_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116690","author":"T Litchman","year":"2020","unstructured":"Litchman T, Roy B, Kumar A, et al. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study. J Neurol Sci. 2020. https:\/\/doi.org\/10.1016\/j.jns.2020.116690.","journal-title":"J Neurol Sci"},{"key":"557_CR21","doi-asserted-by":"publisher","unstructured":"Nelke C, Schroeter CB, Stascheit F et al. Eculizumab versus rituximab in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2022.\u00a0https:\/\/doi.org\/10.1136\/jnnp-2021-328665.","DOI":"10.1136\/jnnp-2021-328665"},{"key":"557_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.05.004","author":"S Jing","year":"2019","unstructured":"Jing S, Lu J, Song J, et al. Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis. J Neuroimmunol. 2019. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.05.004.","journal-title":"J Neuroimmunol"},{"key":"557_CR23","doi-asserted-by":"publisher","unstructured":"G\u00f6l MF, Kara F, Boz M et al. Effects of rituximab on prognosis in myasthenia gravis: A single-center experience from Turkey. Ideggy\u00f3gy\u00e1szati Szemle 2022.\u00a0https:\/\/doi.org\/10.18071\/isz.75.0351.","DOI":"10.18071\/isz.75.0351"},{"key":"557_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14391","author":"A Dos Santos","year":"2020","unstructured":"Dos Santos A, Noury JB, Genestet S, et al. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study. Eur J Neurol. 2020. https:\/\/doi.org\/10.1111\/ene.14391.","journal-title":"Eur J Neurol"},{"key":"557_CR25","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180300","author":"O Landon-Cardinal","year":"2018","unstructured":"Landon-Cardinal O, Friedman D, Guiguet M, et al. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis. J Neuromuscul Dis. 2018. https:\/\/doi.org\/10.3233\/JND-180300.","journal-title":"J Neuromuscul Dis"},{"key":"557_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13468","author":"C Zhang","year":"2020","unstructured":"Zhang C, Bu B, Yang H, et al. Immunotherapy choice and maintenance for generalized myasthenia gravis in China. CNS Neurosci Ther. 2020. https:\/\/doi.org\/10.1111\/cns.13468.","journal-title":"CNS Neurosci Ther"},{"key":"557_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.564","author":"E Cort\u00e9s Vicente","year":"2018","unstructured":"Cort\u00e9s Vicente E, Rojas Garcia R, D\u00edazManera J, et al. The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Ann Clin Transl Neurol. 2018. https:\/\/doi.org\/10.1002\/acn3.564.","journal-title":"Ann Clin Transl Neurol"},{"key":"557_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11048-4","author":"Y Du","year":"2022","unstructured":"Du Y, Li C, Hao Y, et al. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis. J Neurol. 2022. https:\/\/doi.org\/10.1007\/s00415-022-11048-4.","journal-title":"J Neurol"},{"key":"557_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982","author":"J D\u00edaz-Manera","year":"2012","unstructured":"D\u00edaz-Manera J, Mart\u00ednez-Hern\u00e1ndez E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012. https:\/\/doi.org\/10.1212\/WNL.0b013e3182407982.","journal-title":"Neurology"},{"key":"557_CR30","doi-asserted-by":"publisher","unstructured":"Chan F, Swayne A, Gillis D et al. Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab. J Neurol Neurosurg Psychiatry. 2019.\u00a0https:\/\/doi.org\/10.1136\/jnnp-2018-319410.","DOI":"10.1136\/jnnp-2018-319410"},{"key":"557_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000420","author":"JI Castiglione","year":"2022","unstructured":"Castiglione JI, Rivero AD, Barroso F, et al. Long-term remission with low-dose rituximab in myasthenia gravis: a retrospective study. J Clin Neuromuscul Dis. 2022. https:\/\/doi.org\/10.1097\/CND.0000000000000420.","journal-title":"J Clin Neuromuscul Dis"},{"key":"557_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26790","author":"J Lu","year":"2020","unstructured":"Lu J, Zhong H, Jing S, et al. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor\u2013positive refractory generalized myasthenia gravis. Muscle Nerve. 2020. https:\/\/doi.org\/10.1002\/mus.26790.","journal-title":"Muscle Nerve"},{"key":"557_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577383","author":"H Zhong","year":"2020","unstructured":"Zhong H, Lu J, Jing S, et al. Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients. J Neuroimmunol. 2020. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577383.","journal-title":"J Neuroimmunol"},{"key":"557_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577528","author":"H Li","year":"2021","unstructured":"Li H, Huang Z, Jia D, et al. Low-dose rituximab treatment for new-onset generalized myasthenia gravis. J Neuroimmunol. 2021. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577528.","journal-title":"J Neuroimmunol"},{"key":"557_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000013121","author":"RJ Nowak","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology. 2022. https:\/\/doi.org\/10.1212\/WNL.0000000000013121.","journal-title":"Neurology"},{"key":"557_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419871187","author":"K Choi","year":"2019","unstructured":"Choi K, Hong Y, Ahn S, et al. Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis. Ther Adv Neurol Disord. 2019. https:\/\/doi.org\/10.1177\/1756286419871187.","journal-title":"Ther Adv Neurol Disord"},{"key":"557_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/1756285611411503","author":"RJ Nowak","year":"2011","unstructured":"Nowak RJ, DiCapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord. 2011. https:\/\/doi.org\/10.1177\/1756285611411503.","journal-title":"Ther Adv Neurol Disord"},{"key":"557_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27393","author":"CT Doughty","year":"2021","unstructured":"Doughty CT, Suh J, David WS, Amato AA, Guidon AC. Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients \u226565 years old. Muscle Nerve. 2021. https:\/\/doi.org\/10.1002\/mus.27393.","journal-title":"Muscle Nerve"},{"key":"557_CR39","doi-asserted-by":"publisher","unstructured":"Ziaadini B, Karimi N, Panahi A et al. A retrospective study of the safety and efficacy of rituximab in Iranian patients with myasthenia gravis: A single-center experience. Curr J Neurol. 2022.\u00a0https:\/\/doi.org\/10.18502\/cjn.v21i2.10492.","DOI":"10.18502\/cjn.v21i2.10492"},{"key":"557_CR40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004341","author":"MK Hehir","year":"2017","unstructured":"Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology. 2017. https:\/\/doi.org\/10.1212\/WNL.0000000000004341.","journal-title":"Neurology"},{"key":"557_CR41","doi-asserted-by":"publisher","DOI":"10.4103\/0028-3886.359277","author":"S Shivaram","year":"2022","unstructured":"Shivaram S, Nagappa M, Varghese N, et al. Rituximab in Myasthenia Gravis- Experience from a Low- and Middle-Income Country (LMIC) Setting. Neurol India. 2022. https:\/\/doi.org\/10.4103\/0028-3886.359277.","journal-title":"Neurol India"},{"key":"557_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.06.006","author":"M Caballero-\u00c1vila","year":"2022","unstructured":"Caballero-\u00c1vila M, \u00c1lvarez-Velasco R, Moga E, et al. Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia. Neuromuscul Disord. 2022. https:\/\/doi.org\/10.1016\/j.nmd.2022.06.006.","journal-title":"Neuromuscul Disord"},{"key":"557_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23412","author":"N Collongues","year":"2012","unstructured":"Collongues N, Casez O, Lacour A, et al. Rituximab in refractory and non-refractory myasthenia: A retrospective multicenter study. Muscle Nerve. 2012. https:\/\/doi.org\/10.1002\/mus.23412.","journal-title":"Muscle Nerve"},{"key":"557_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26156","author":"G Beecher","year":"2018","unstructured":"Beecher G, Anderson D, Siddiqi ZA. Rituximab in refractory myasthenia gravis: Extended prospective study results. Muscle Nerve. 2018. https:\/\/doi.org\/10.1002\/mus.26156.","journal-title":"Muscle Nerve"},{"key":"557_CR45","doi-asserted-by":"publisher","unstructured":"Rashid AA, Almashta SA, Hussein RA, Mashaallah AK. Rituximab in the Treatment of Refractory Myasthenia Gravis: Studying the Outcomes using MMT Score and Need for Plasmapheresis in Baghdad Teaching Hospital. Indian J Forensic Med Toxicol. 2020.\u00a0https:\/\/doi.org\/10.37506\/ijfmt.v14i2.3108.","DOI":"10.37506\/ijfmt.v14i2.3108"},{"key":"557_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27233","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Yan C, Gu X, et al. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody. Muscle Nerve. 2021. https:\/\/doi.org\/10.1002\/mus.27233.","journal-title":"Muscle Nerve"},{"key":"557_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120394","author":"JM Heckmann","year":"2022","unstructured":"Heckmann JM. A single low-dose rituximab infusion in severe chronic refractory myasthenia gravis in resource-limited settings. J Neurol Sci. 2022. https:\/\/doi.org\/10.1016\/j.jns.2022.120394.","journal-title":"J Neurol Sci"},{"key":"557_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.06.002","author":"RH Roda","year":"2019","unstructured":"Roda RH, Doherty L, Corse AM. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis. Neuromuscul Disord. 2019. https:\/\/doi.org\/10.1016\/j.nmd.2019.06.002.","journal-title":"Neuromuscul Disord"},{"key":"557_CR49","doi-asserted-by":"publisher","unstructured":"Blum S, Gillis D, Brown H et al. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011.\u00a0https:\/\/doi.org\/10.1136\/jnnp.2010.220475.","DOI":"10.1136\/jnnp.2010.220475"},{"key":"557_CR50","doi-asserted-by":"publisher","unstructured":"Maddison P, McConville J, Farrugia ME et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011.\u00a0https:\/\/doi.org\/10.1136\/jnnp.2009.197632.","DOI":"10.1136\/jnnp.2009.197632"},{"key":"557_CR51","doi-asserted-by":"publisher","DOI":"10.1159\/000534336","author":"J Ren","year":"2023","unstructured":"Ren J, Wang J, Liu R, et al. Long-term efficacy and safety of low-dose rituximab in patients with refractory myasthenia gravis. Eur Neurol. 2023. https:\/\/doi.org\/10.1159\/000534336.","journal-title":"Eur Neurol"},{"key":"557_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-07082-3","author":"Z Kefalopoulou","year":"2024","unstructured":"Kefalopoulou Z, Veltsista D, Germeni A, et al. Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes. Neurol Sci. 2024. https:\/\/doi.org\/10.1007\/s10072-023-07082-3.","journal-title":"Neurol Sci"},{"issue":"4","key":"557_CR53","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","volume":"91","author":"V Di Stefano","year":"2020","unstructured":"Di Stefano V, Lupica A, Rispoli MG, et al. Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neuros Psychiatry. 2020;91(4):392\u20135. https:\/\/doi.org\/10.1136\/jnnp-2019-322606.","journal-title":"J Neurol Neuros Psychiatry"},{"key":"557_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116648","author":"M John","year":"2020","unstructured":"John M, Li Y. Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci. 2020. https:\/\/doi.org\/10.1016\/j.jns.2019.116648.","journal-title":"J Neurol Sci"},{"key":"557_CR55","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19416","author":"S Bastakoti","year":"2021","unstructured":"Bastakoti S, Kunwar S, Poudel S, et al. Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis. Cureus. 2021. https:\/\/doi.org\/10.7759\/cureus.19416.","journal-title":"Cureus"},{"key":"557_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00613","author":"M Marino","year":"2020","unstructured":"Marino M, Basile U, Spagni G, et al. Long-Lasting Rituximab-Induced Reduction of Specific\u2014But Not Total\u2014IgG4 in MuSK-Positive Myasthenia Gravis. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.00613.","journal-title":"Front Immunol"},{"key":"557_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0110-z","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019. https:\/\/doi.org\/10.1038\/s41582-018-0110-z.","journal-title":"Nat Rev Neurol"},{"key":"557_CR58","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2021. https:\/\/doi.org\/10.1212\/WNL.0000000000011124.","journal-title":"Neurology"},{"key":"557_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7532-3","author":"R Iorio","year":"2015","unstructured":"Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2015. https:\/\/doi.org\/10.1007\/s00415-014-7532-3.","journal-title":"J Neurol"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-025-00557-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-025-00557-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-025-00557-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T01:00:33Z","timestamp":1745542833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-025-00557-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["557"],"URL":"https:\/\/doi.org\/10.1007\/s40199-025-00557-y","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"3 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used in this study are all from the published literature. These data are publicly available and do not contain any sensitive personal data. Therefore, we believe that ethical approval and consent to participate are not applicable to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}